All News
#ACR21 @RheumNow
Abst#0450 Hwang et al. from the PSOAS cohort analyzed 1618 radiographs between 2002-2017
⭐️Higher spinal disease: Male gender; longer disease duration; smoking
⭐️🔼Disease progression 🔼CRP levels
⭐️🔽Disease progression with time-varying TNFI use https://t.co/XsKp28HOxz
swethaann23 swethaann23 ( View Tweet)
Pre clinical RA: don't miss the feet 🦶🏼! Among 577 patients
with clinically suspect arthralgia undergoing MRI:
-23% intermetatarsal bursitis > ACPA + 56% vs. 19%
-higher risk or RA HR 3.3.
Would we find the same results w/ US?
#OP0468 @RheumNow #ACR2021 https://t.co/VkzUu93qGq https://t.co/GGw7UgdPVR
Aurelie Najm AurelieRheumo ( View Tweet)
Accdg to this study by Dr. B VanDijk et al, intermetatarsal bursitis (IMB) was seen in 23% of clin suspect arthralgia(CSA) pts; predicted clinical arthritis in ACPA+; ⬆ frequent w/ synovitis & tenosynovitis
Addtl tool for early RA dx?
@RheumNow #ACR21 abs0468 #ACRBest https://t.co/bcUuy8bHLJ
sheila RHEUMarampa ( View Tweet)
AxSpA pts share a gut microbiome signature with Crohn's disease and anterior uveitis pts
⬇️Blautia
⬆️Veillonella and Lactobacillus
⭐️SpA pts uniquely enriched in Collinsella
Abs#0062 #ACR21 @RheumNow #ACRBest
https://t.co/sdlHxNbhr8 https://t.co/r8eG9c9vwa
Robert B Chao, MD doctorRBC ( View Tweet)
Early axSpA DESIR: higher dz activity & worse function independently assoc'd w/ ^ hazard of Work Disability vs SES. Dz severity strong predictor of adverse work outcome despite advanced therapeutic strategies in axSpA. Abs 0381 #ACR21 #RheumNow @RheumNow https://t.co/Lc3yUgXvw6
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR21 Abst#0455 ARIAA Study: Abatacept for subclinical arthritis
⭐️ ACPA + arthralgia + MRI inflammation 🔥
⭐️ ⬇️ MRI inflam (primary) and ⬇️ progression to arthritis (secondary)
▶️ Many patients likely early RA, would still rec starting MTX 1st
https://t.co/4aREvqlpUI @Rheumnow https://t.co/vqRgsd75Il
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 Abst#0293:
Lung involvement in 67 sero+ RA pts assoc w/:
⭐︎ SSc-specific ab
➡️ RP155, Th/To, fibrillarin, NOR90 in ILD group
➡️ Ku, Pm/Scl100, CENP-A/B in non-ILD group
⭐︎ older age, ⚦ sex, heavy 🚬
⭐︎ ↑ WBC, CRP, RF
#ACRBest @Rheumnow
https://t.co/Yo4jRKqvfV https://t.co/l5gbKoZBkm
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Yikes! Higher rates of lupus nephritis deaths in last 5 years
👉8900 lupus nephritis deaths in USA studied
race/ethnicity and urbanization assc w/ LN mortality
👉highest in blacks and large central metro regions
#ACR21 #Plenary Abstr# 0454 @rheumnow https://t.co/bxQvID8jht
TheDaoIndex KDAO2011 ( View Tweet)
Nice graphic presentation of the results! Dr. Katie Liao and her group present the characteristics and disease manifestations of Ro+ #SLE patients from the Australian #lupus registry and biobank
@RheumNow #ACR21 abs0323 https://t.co/Yl5sZgiTw1
sheila RHEUMarampa ( View Tweet)
ARIAA study of abatacept in pre-RA. Abatacept ⬇️MRI inflammation and reduces progression to RA. Of course it does. Like all these studies, really not sure what this is telling us. Abstr#0455 #ACR21 @RheumNow https://t.co/yNVVZFBWDq
Richard Conway RichardPAConway ( View Tweet)
Is it time to consider targeting gut microbiome for treatment of AS?
Large study identified:
⭐️Ruminococcus torques associated with FUT2 gene influences risk of developing AS
Abs#0068
https://t.co/E1hL18KZbQ
#ACR21
#ACRBest
@RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR21 #Abstr0454 Mortality rate in #lupus nephritis ⬇️by 26% from 1999-2019👏. BUT, racial and residence disparities were concerning; worse in Black, Hispanic, Asian, AI/AN vs White and in large central and medium metro. Residential matters! @RheumNow https://t.co/33vN39acuL https://t.co/XMwN2hXJn7
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Possible disease activity biomarkers in axSpA? Neutrophil lymphocyte ratio (NLR) & platelet lymphocyte ratio (PLR) along w/ PROs may be helpful to measure dz activity clinically. More studies needed for proof of concept. Abs 0384 #ACR21 #RheumNow @RheumNow https://t.co/ZXyQHNzqz7 https://t.co/va5fBR9Gnk
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR21 @RheumNow
Abst#0370 by Afinogenova et al.
138 PCP surveyed on Chronic back pain evaluation
▶️58% rarely assess for IBP
▶️40% not comfortable diagnosing AS
▶️70% not comfortable diagnosing axSpA
Contributing to a lack of referral to rheumatology and delay in diagnosis.
swethaann23 swethaann23 ( View Tweet)
Annual age-standardized mortality rate (ASMR) improved from 1999-2015, then worsened 2015-2019:
#ACR21 Abst#0454 @RheumNow https://t.co/mu1xIO7YlI
Pedro Castillo _Castillo_Pedro ( View Tweet)
Race/ethnicity and residence were independent risk factors for LN mortality which was higher in:
➡️Black patients
➡️Those living in central metro areas
#ACR21 Abst#0454 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Prevention study using Abatacept in 100 patients with arthralgia is superior (61%) to placebo (31%) in improving subclinical inflammation in RA at-risk patients (ACPA+, MRI+, Arthralgia+) at 6 months. No new safety issue emerged @RheumNow #ACR21 Abst#0455 https://t.co/DoRItcHfBE
Dr. Antoni Chan synovialjoints ( View Tweet)
Abst0453 #ACR21 @RheumNow integrated phase 2/3 trial results of il23 inhibitor Risankizumab (RZB) in PsA: significant improvement ACR20 at Week 24 (RZB 55.5% vs PBO 31.3%, P < 0.001), secondary endpoint met at HAQ DI, PASI, fatigue score& enthesitis. no new safety signals https://t.co/ZAVgswoXCf
Olga Petryna DrPetryna ( View Tweet)
#ACR21 Abst#0456. Fxnal connectivity, ⬆️ blood-brain barrier (BBB) leakage & cognitive impairment (CI) in SLE
⭐️SLE pts ⬆️♀️, older, caucasian, ⬇️ edu than controls
⭐️CI in longer disease, APS
▶️ SLE CI:⬇️Brain-wide connections, BBB permeability
https://t.co/fen9OYhWhC @Rheumnow https://t.co/DMQfWCqUhh
Links:
Eric Dein ericdeinmd ( View Tweet)
RZB tx resulted in statistically greater improvements in signs/ symptoms of PsA vs PBO and was well tolerated w/ no new safety signals. Plenary Abs 0453 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/c9RJdWlmpO https://t.co/MDbdAhdnIy
Dr. Rachel Tate uptoTate ( View Tweet)